|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RASSF8 |
Gene summary for RASSF8 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RASSF8 | Gene ID | 11228 |
| Gene name | Ras association domain family member 8 | |
| Gene Alias | C12orf2 | |
| Cytomap | 12p12.1 | |
| Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | A0A024RB12 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11228 | RASSF8 | HCC1_Meng | Human | Liver | HCC | 2.46e-16 | -1.35e-01 | 0.0246 |
| 11228 | RASSF8 | HCC2_Meng | Human | Liver | HCC | 4.91e-02 | -1.20e-01 | 0.0107 |
| 11228 | RASSF8 | HCC1 | Human | Liver | HCC | 1.69e-03 | 2.21e+00 | 0.5336 |
| 11228 | RASSF8 | HCC2 | Human | Liver | HCC | 1.04e-03 | 9.71e-01 | 0.5341 |
| 11228 | RASSF8 | RNA-P10T2-P10T2-3 | Human | Lung | AAH | 3.00e-05 | 8.85e-01 | -0.1408 |
| 11228 | RASSF8 | RNA-P10T2-P10T2-4 | Human | Lung | AAH | 2.53e-03 | 7.65e-01 | -0.138 |
| 11228 | RASSF8 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 2.50e-09 | 5.70e-01 | -0.2116 |
| 11228 | RASSF8 | RNA-P25T1-P25T1-2 | Human | Lung | AIS | 2.02e-02 | 5.22e-01 | -0.1941 |
| 11228 | RASSF8 | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 9.47e-08 | 7.03e-01 | -0.2107 |
| 11228 | RASSF8 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 9.22e-13 | 7.15e-01 | -0.2119 |
| 11228 | RASSF8 | RNA-P6T1-P6T1-2 | Human | Lung | MIAC | 4.36e-02 | 8.04e-01 | -0.0186 |
| 11228 | RASSF8 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 2.65e-09 | 4.03e-01 | -0.0166 |
| 11228 | RASSF8 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 1.01e-10 | 3.65e-01 | -0.0132 |
| 11228 | RASSF8 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 2.01e-08 | 2.94e-01 | -0.013 |
| 11228 | RASSF8 | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 5.94e-08 | 3.66e-01 | -0.0121 |
| 11228 | RASSF8 | RNA-P8T2-P8T2-3 | Human | Lung | AIS | 1.70e-02 | 6.75e-01 | -0.1284 |
| 11228 | RASSF8 | GSM5252132_BPH389PrGF | Human | Prostate | BPH | 1.14e-15 | 9.98e-01 | -0.2247 |
| 11228 | RASSF8 | 047563_1562-all-cells | Human | Prostate | BPH | 5.25e-11 | 4.37e-01 | 0.0791 |
| 11228 | RASSF8 | 048752_1579-all-cells | Human | Prostate | BPH | 6.82e-27 | 7.40e-01 | 0.1008 |
| 11228 | RASSF8 | 052095_1628-all-cells | Human | Prostate | BPH | 5.46e-05 | 3.59e-01 | 0.1032 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RASSF8 | SNV | Missense_Mutation | novel | c.298N>G | p.Thr100Ala | p.T100A | Q8NHQ8 | protein_coding | tolerated(0.21) | benign(0.039) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| RASSF8 | SNV | Missense_Mutation | c.777N>T | p.Lys259Asn | p.K259N | Q8NHQ8 | protein_coding | tolerated(0.45) | benign(0.007) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| RASSF8 | SNV | Missense_Mutation | novel | c.953N>T | p.Ala318Val | p.A318V | Q8NHQ8 | protein_coding | deleterious(0.03) | benign(0.056) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| RASSF8 | SNV | Missense_Mutation | novel | c.667N>C | p.Glu223Gln | p.E223Q | Q8NHQ8 | protein_coding | deleterious(0.02) | benign(0.166) | TCGA-C5-A8YR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| RASSF8 | SNV | Missense_Mutation | novel | c.541N>A | p.Glu181Lys | p.E181K | Q8NHQ8 | protein_coding | deleterious(0.01) | benign(0.22) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| RASSF8 | SNV | Missense_Mutation | c.501G>T | p.Lys167Asn | p.K167N | Q8NHQ8 | protein_coding | tolerated(0.3) | benign(0.011) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| RASSF8 | SNV | Missense_Mutation | novel | c.435N>C | p.Lys145Asn | p.K145N | Q8NHQ8 | protein_coding | tolerated(0.07) | benign(0.146) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RASSF8 | SNV | Missense_Mutation | novel | c.644N>T | p.Arg215Ile | p.R215I | Q8NHQ8 | protein_coding | deleterious(0.01) | benign(0.07) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| RASSF8 | SNV | Missense_Mutation | novel | c.159N>C | p.Leu53Phe | p.L53F | Q8NHQ8 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AJ-A23O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RASSF8 | SNV | Missense_Mutation | rs746967473 | c.985N>T | p.Arg329Cys | p.R329C | Q8NHQ8 | protein_coding | deleterious(0.01) | possibly_damaging(0.818) | TCGA-AJ-A8CT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |